https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-12 / Hum Vaccin Immunother 2019;15(2):397-406
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-12 / Hum Vaccin Immunother 2019;15(2):397-4062018-10-12 00:00:002019-03-25 10:39:48Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-11 / Exp Ther Med 2018 Dec;16(6):5123-5129
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-11 / Exp Ther Med 2018 Dec;16(6):5123-51292018-10-11 00:00:002018-10-11 00:00:00Dendritic cell vaccine with Ag85A enhances anti-colorectal carcinoma immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-10 / Cancer Immunol. Immunother. 2019 Jan;68(1):121-130
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-10 / Cancer Immunol. Immunother. 2019 Jan;68(1):121-1302018-10-10 00:00:002019-03-25 10:37:19Phase I/II clinical trial of a Wilms‘ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-01 / Front Immunol 2018;9:2265
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-01 / Front Immunol 2018;9:22652018-10-01 00:00:002019-02-15 08:36:04Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-10-01 / Am J Clin Dermatol 2018 Oct;19(5):657-670
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-10-01 / Am J Clin Dermatol 2018 Oct;19(5):657-6702018-10-01 00:00:002018-10-01 00:00:00Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-09-29 / J Immunother Cancer 2018 Sep;6(1):96
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-09-29 / J Immunother Cancer 2018 Sep;6(1):962018-09-29 00:00:002019-02-15 08:39:11A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-09-23 / Thorac Cancer 2018 Nov;9(11):1437-1452
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-09-23 / Thorac Cancer 2018 Nov;9(11):1437-14522018-09-23 00:00:002019-02-15 08:45:47Recombinant Newcastle disease virus expressing human IFN-λ1 (rL-hIFN-λ1)-induced apoptosis of A549 cells is connected to endoplasmic reticulum stress pathways
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-09-07 / Front Immunol 2018;9:2034
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-09-07 / Front Immunol 2018;9:20342018-09-07 00:00:002020-09-07 08:00:31Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-29 / CNS Oncol 2018 07;7(3):CNS22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-29 / CNS Oncol 2018 07;7(3):CNS222018-08-29 00:00:002019-02-15 09:00:10Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte counts
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-23 / Ann Res Hosp 2018 Aug;2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-23 / Ann Res Hosp 2018 Aug;22018-08-23 00:00:002020-02-05 10:32:52Further clinical advancement of dendritic cell vaccination against ovarian cancer
